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Background: Mitochondrial KATP channel activation is an essential component of
ischemic preconditioning. These channels are selectively opened by diazoxide and
may be up-regulated by adenosine and nitric oxide. Therefore, pharmacological
preconditioning with diazoxide in combination with adenosine and a nitric oxide
donor (triple-combination pharmacological preconditioning) may enhance cardio-
protection.
Methods and Results: Isolated and perfused rat hearts underwent ischemic precon-
ditioning with 3 cycles of 5 minutes of ischemia and 5 minutes of reperfusion before
5 minutes of oxygenated potassium cardioplegia and 35 minutes of ischemia.
Pharmacological preconditioning was performed by adding adenosine, diazoxide,
and a nitric oxide donor S-nitroso-N-acetyl-penicillamine each alone or in combi-
nations for 25 minutes followed by 10 minutes washout before cardioplegic arrest.
Only triple-combination pharmacological preconditioning conferred significant car-
dioprotection as documented by highly improved left ventricular function and
limited creatine kinase release during reperfusion that was comparable to that
afforded by ischemic preconditioning. Mitochondrial KATP channel activity as-
sessed by flavoprotein oxidation was increased by diazoxide, but no further increase
in flavoprotein oxidation was obtained by ischemic preconditioning and triple-
combination pharmacological preconditioning. Significant activation of protein ki-
nase C- was observed in only ischemic preconditioning and triple-combination
pharmacological preconditioning. Pretreatment with the mitochondrial KATP chan-
nel inhibitor 5-hydroxydecanoate or the protein kinase C inhibitor chelerythrine
abrogated activation of protein kinase C- and cardioprotection afforded by isch-
emic preconditioning and triple-combination pharmacological preconditioning.
Conclusions: Integrated pharmacological preconditioning is not simply mediated by
enhanced mitochondrial KATP channel activation, but is presumably mediated
through amplified protein kinase C signaling promoted by coordinated interaction of
adenosine, mitochondrial KATP channel activation, and nitric oxide.
We have previously demonstrated that the efficacy of ischemicpreconditioning (IPC) under potassium cardioplegia is de-pendent on the grade of IPC.1 Low-grade IPC induced by arepeated brief period of ischemia does not enhance myocar-dial protection over potassium cardioplegia, although high-grade-IPC induced by a repeated longer period of ischemia
enhances myocardial protection conferred by potassium cardioplegia. Although IPC
is a powerful endogenous form of myocardial protection, application of high-grade
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ischemic stress as a preconditioning challenge is limited in
the clinical setting of myocardial protection. This is because
the graded phenomenon of IPC has not been demonstrated
in human subjects, and clinical trials to identify optimal IPC
protocols may not be allowed from an ethical point of view.
Thus, pharmacological preconditioning (PPC) represents an
ideal alternative to IPC, and greater effort should be exerted
to invent pharmacological tools that mimic high-grade IPC.
A major issue in exploring the strategy for successful
PPC was obtaining a reliable indicator for cardioprotective
signaling. Although the exact signaling cascades generated
by IPC have been poorly understood, accumulating evi-
dence suggests that protein kinase C (PKC) activation is a
key event in IPC-mediated signal transduction responsible
for myocardial protection.2,3 Our previous study1 demon-
strated that low-grade IPC is associated with activation of
only Ca2-dependent classical isoform of PKC, while high-
grade IPC also activates Ca2-independent novel isoform of
PKC associated with greater myocardial protection than
low-grade IPC. Among the novel isoform of PKC, PKC-
has been shown to be an essential molecular link between
preconditioning and cardiomyocyte protection.4,5 There-
fore, it is suggested that PKC- activity represents the
magnitude of cardioprotective signaling provoked by IPC
and PPC.
Mitochondrial KATP (mitoKATP) channels have been im-
plicated in the trigger of IPC6 and, thus, mitoKATP channel
opener diazoxide has been employed as a tool of PPC.7
Diazoxide-induced mitoKATP channel activation could be
enhanced by adenosine and nitric oxide (NO), which are
also known as the triggers of IPC.8,9 It has been shown that
adenosine primes opening of mitoKATP channels by diazox-
ide10 and NO enhances diazoxide-induced activation of
mitoKATP channels.10 Therefore, it is anticipated that the
powerful myocardial protection conferred by IPC compared
with any single PPC strategies may be accounted for by a
highly activated state of mitoKATP channels under the com-
bined effect of these agents. If this assumption is true, PPC
in combination with adenosine, diazoxide, and a NO donor
(triple combination PPC; TPPC) could enhance the cardio-
protection afforded by each drug alone by augmenting mi-
toKATP channel activity. Alternatively, robust cardioprotec-
tion could be promoted by coordinated interaction of
distinct cellular events induced by adenosine, mitoKATP
channel activation, and NO that amplifies PKC signaling
responsible for cardioprotection. The present study was
designed to address this issue.
Materials and Methods
Perfusion Technique
Male Sprague-Dawley rats weighing 250 to 300 g were used in the
present study. All experiments were conducted in accordance with
the “Guidelines for the Care and Use of Laboratory animals” (NIH
publication No. 86-23, revised 1985). The rat hearts were excised
and perfused as described previously1 except that CaCl2 of Krebs-
Henseleit bicarbonate (KHB) buffer solution was reduced to 1.8
mmol/L.
Isovolumic left ventricular (LV) function was measured as
described previously.1 The hearts with LV-developed pressure
(LVDP) lower than 80 mm Hg or heart rate less than 240 bpm at
the baseline were excluded from the study. LVDP, heart rate, and
coronary flow were expressed as a percentage of the baseline
values.
Experimental Protocol
The hearts were randomly assigned to 15 groups (Figure 1).
Time-matched control hearts underwent 45 minutes of normal
perfusion before 5 minutes of oxygenated potassium cardioplegia
(PCP) followed by 35 minutes of global ischemia and 30 minutes
of reperfusion. The composition of PCP was the same as that of
KHB buffer solution except that the concentration of KCl was
increased to 20 mmol/L with equimolar reduction of NaCl. IPC
was introduced by 3 cycles of 5 minutes of ischemia and 5 minutes
of reperfusion. The last reperfusion of IPC was extended to 10
minutes. PPC groups of hearts received 30 mol/L adenosine, 50
mol/L diazoxide, and 50 mol/L S-nitroso-N-acetyl-penicilla-
mine (SNAP), with each drug either alone or in combinations of
two or three drugs for 25 minutes followed by 10 minutes of
drug-free perfusion before PCP. The mitoKATP channel inhibitor
5-hydroxydecanoic acid (5-HD; 0.5 mmol/L) or the PKC inhibitor
chelerythrine (5 mol/L) was administered for 45 minutes before
PCP with or without IPC or TPPC. Adenosine, diazoxide, and
chelerythrine were obtained from Sigma Chemical Co. SNAP was
purchased from Wako Pure Chemical Co, and 5-HD was obtained
from Biomol Research Labs, Inc. Diazoxide, SNAP, and chel-
erythrine were dissolved in dimetylsulfoxide. The final concentra-
tion of dimetylsulfoxide was 0.05%.
Coronary effluent was collected during 30 minutes of reperfu-
sion, and creatine kinase (CK) activity was measured as described
previously1 to assess the severity of cardiomyocyte necrosis. At
the end of experiments, a piece of the left ventricular tissue was
excised to determine the wet/dry ratio.
Flavoprotein Fluorescence Measurement
The isolated rat heart was placed in a temperature-regulated heart
chamber installed in a CAF-110 intracellular ion analyzer (Japan
Spectroscopic Co) and was perfused as described above. The
experimental system uses a dual-wavelength spectrofluorimeter for
exciting and detecting flavoprotein autofluorescence. Fluorescence
excitation was provided by a xenon lamp with a band-pass filter
centered at 480 nm. The excitation light was diverted onto a
circular region of the LV epicardium in diameter of 1 cm by a
dichroic mirror. Fluorescence then passed through an emission
filter centered at 530 nm before reaching a photomultiplier. Pho-
tomultiplier output was digitized and the fluorescence was dis-
played on a strip-chart recorder. At the end of each experiment
dinitrophenol (DNP; 1 mmol/L) was added to elicit full oxidation
of mitochondrial flavoprotein. Data were expressed as a percentage
of the DNP-induced fluorescence.
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Tissue Sample Preparation and PKC--Selective
Phosphorylation Activity Assay
In the experiments on PKC--selective phosphorylation activity
assay, LV myocardium of approximately 500 mg was excised just
before cardioplegic arrest. The myocardial samples were immedi-
ately frozen in liquid nitrogen. The particulate and the cytosol
fractions were isolated, and the phosphorylation activity of the
-isoform of PKC was determined as described previously.11
Briefly, 50 g of protein from either the particulate or the cytosol
fraction were immunoprecipitated overnight with PKC- antibod-
ies (Santa Cruz Biotechnology). The immunoprecipitates were
then subjected to a phosphorylation assay using a PKC assay kit
(Upstate Biotechnology).
Statistical Analysis
All numerical data are expressed as mean  SEM. Statistical
analysis was performed by 1-way ANOVA, followed by the Bon-
ferroni post hoc test.
Results
IPC and TPPC Improve Postischemic Myocardial
Performance
None of the baseline hemodynamic variables significantly
differed among the experimental groups. LVDP was signif-
icantly (P .01) depressed during IPC (Figure 2). Although
adenosine, diazoxide, and their combinations had no signif-
icant (P  .2) effect on LVDP during preconditioning,
SNAP and its combination with diazoxide significantly (P
 .05) increased LVDP during preconditioning. However,
TPPC did not significantly (P  .2) affect LVDP during
preconditioning. Heart rate was significantly reduced by
preconditioning with adenosine (P  .01) and its combina-
tion with diazoxide (P .01) or SNAP (P .05). Coronary
flow was markedly (P  .01) increased by IPC. A similar
increase in coronary flow was noted during PPC with aden-
osine and SNAP alone. Diazoxide also produced significant
(P  .05) increase in coronary flow. PPC in combination
Figure 1. Experimental protocols. Control group (n  7) underwent 5 minutes of normothermic oxygenated
potassium cardioplegia (shaded box) followed by 35 minutes of global ischemia (filled box) and 30 minutes of
reperfusion. Ischemic preconditioning (IPC) group (n 7) received 3 cycles of 5 minutes of ischemia and 5 minutes
of reperfusion. Single pharmacological preconditioning (SPPC) groups (n  7) received adenosine (Ad) or
diazoxide (Dz) or S-nitroso-N-acetyl-penicillamine (SNAP) for 25 minutes. Double combination pharmacological
preconditioning (DPPC) groups (n  6) received Ad  Dz or Ad  SNAP or Dz  SNAP for 25 minutes.
Triple-combination pharmacological preconditioning (TPPC) group (n  7) received Ad  Dz  SNAP for 25
minutes. All PPC groups underwent 10 minutes of drug-free perfusion before cardioplegic arrest. In 6 groups of
hearts (n  6 each) treated with 5-hydroxydecanoate (HD) or chelerythrine (Che), these drugs were administered
for 45 minutes before cardioplegic arrest with or without IPC or TPPC.
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Figure 2. Left ventricular function after preconditioning and reperfusion. Isovolumic left ventricular (LV) function
was measured just prior to cardioplegic arrest in the control and ischemic preconditioning (IPC) hearts. In
pharmacological preconditioning (PPC), hearts with adenosine (Ad), diazoxide (Dz), and S-nitroso-N-acetyl-
penicillamine (SNAP), alone or in combination with two of them or all of them, LV function was measured at the
end of PPC. LV function was also measured 30 minutes after reperfusion. LVDP, HR, and CF indicate LV-developed
pressure, heart rate, and coronary flow, respectively. Each bar graph represents mean  SEM of 6 or 7
experiments. *P < .05, **P < .01 vs control.
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with adenosine and SNAP further increased coronary flow,
but the increase in coronary flow was not additive. No
further increase in coronary flow was noted during TPPC.
Recovery of LVDP after reperfusion was significantly (P
 .01) improved by IPC. Among the PPC groups, only
TPPC conferred significantly (P  .01) better recovery of
LVDP after reperfusion, which was comparable to that
observed with IPC. Similarly, recovery of heart rate after
reperfusion was significantly improved only by IPC (P 
.01) and TPPC (P  .01). Coronary flow was also signifi-
cantly improved only by IPC (P  .05) and TPPC (P 
.01).
IPC and TPPC Accelerate Ischemic Contracture But
Alleviate Postischemic Contracture
LVEDP was not changed during IPC and PPC with any
treatment modalities. LVEDP rose during ischemia, a phe-
nomenon known as “ischemic contracture.” Because we
have previously shown that IPC accelerates ischemic con-
tracture whereas potassium cardioplegia delays it,1 we have
asked whether PPC similarly enhances ischemic contracture
without prior ischemia. Time to the onset of ischemic con-
tracture defined as a 5 mm Hg increase in LVEDP from the
baseline was significantly (P  .05) shortened by IPC
(Table 1). Similar shortening of time to the onset of isch-
emic contracture was observed in only TPPC. Peak contrac-
ture was also significantly (P  .05) increased by IPC and
TPPC. On the contrary, LVEDP 30 minutes after reperfu-
sion was significantly lowered by only IPC (P  .05) and
TPPC (P  .01), although PPC in combination with dia-
zoxide and SNAP marginally (P  .05) lowered LVEDP.
IPC and TPPC Inhibit Postischemic Cardiomyocyte
Necrosis
Although postischemic LV function was significantly im-
proved by IPC and TPPC, functional recovery may not
always be associated with protection against cardiomyocyte
necrosis. Therefore, we have measured CK release during
reperfusion. CK release was significantly inhibited by only
IPC (P  .05) and TPPC (P  .01) compared with control
(Figure 3).
TPPC Does Not Enhance Diazoxide-Induced
Flavoprotein Oxidation
Flavoprotein fluorescence has been measured as an index of
mitoKATP channel activity.10 Therefore, we have measured
flavoprotein fluorescence in the isolated and perfused rat
heart to investigate correlation between mitoKATP channel
activity and cardioprotection (Figure 4). Treatment with 0.5
mmol/L 5-HD, a selective mitoKATP channel blocker, mod-
estly decreased flavoprotein fluorescence (5% of DNP-
induced flavoprotein oxidation) in the normally perfused
heart, indicating that there was only a trivial mitoKATP
channel activity under the baseline condition. Flavoprotein
fluorescence decreased during each cycle of 5 minutes of
ischemia and returned above the baseline during each reper-
fusion. Maximal flavoprotein oxidation was usually ob-
tained between 10 and 15 minutes after the last reperfusion.
Treatment with 5-HD before and during IPC abrogated the
increase in flavoprotein oxidation induced by IPC, suggest-
ing that IPC-induced flavoprotein oxidation was mediated
by activation of mitoKATP channels. In contrast, DNP-
induced flavoprotein oxidation was not affected by 5-HD
(not shown). Diazoxide promptly increased flavoprotein
fluorescence, which reached plateau within 5 minutes. The
magnitude of flavoprotein oxidation was comparable to that
induced by IPC. The increase in flavoprotein oxidation
induced by diazoxide was abrogated by pretreatment with
5-HD. Adenosine treatment induced a transient decline of
flavoprotein oxidation but did not increase flavoprotein ox-
idation thereafter nor did it enhance diazoxide-induced fla-
voprotein oxidation. Subsequent addition of SNAP had also
TABLE 1. Effect of ischemic preconditioning and pharmacological preconditioning on ischemic contracture, end-diastolic
pressure, and peak systolic pressure after reperfusion
TTC
(minutes)
Peak contracture
(mm Hg)
LVEDP R30
(mm Hg)
Peak systolic pressure
R30 (mm Hg)
Control (n  7) 21 2 35 2 34 3 93 4
IPC (n  7) 15 1* 50 3* 18 3* 103 4
Ad (n  7) 21 1 36 3 29 3 93 6
Dz (n  7) 22 1 36 3 28 3 91 3
SNAP (n  7) 18 2 41 3 27 4 92 6
Ad  Dz (n  6) 21 2 39 3 26 5 94 4
Ad  SNAP (n  6) 18 2 41 4 27 2 95 6
Dz  SNAP (n  6) 19 2 41 4 24 4 94 6
Ad  Dz  SNAP (n  7) 14 1* 47 3* 10 3* 106 5
TTC, Time to the onset of ischemic contracture; LVEDP R30, left ventricular end-diastolic pressure 30 minutes after reperfusion; IPC, ischemic
preconditioning; Ad, adenosine; Dz, diazoxide; SNAP, S-nitroso-N-acetyl-penicillamine.
Data are expressed as mean  SEM.
*P  .01 vs control.
Cardiopulmonary Support and Physiology Uchiyama et al
152 The Journal of Thoracic and Cardiovascular Surgery ● July 2003
CSP
no appreciable effect on diazoxide-induced flavoprotein ox-
idation. Quantitative analysis showed that maximal fla-
voprotein oxidation induced by IPC and TPPC was not
significantly different (P  .2) from that induced by dia-
zoxide alone. Flavoprotein oxidation induced by IPC, dia-
zoxide, and TPPC was significantly inhibited by pretreat-
ment with 5-HD.
IPC and TPPC Activate PKC- and Inhibition of
PKC- Activity by 5-HD or by a PKC Inhibitor
Abrogates Cardioprotection
Because activation of PKC- is an essential molecular link
between IPC and myocardial protection,4,5 we have mea-
sured activity of this novel PKC isoform in preconditioned
hearts. PKC- activity in the particulate fraction was signif-
icantly (P  .01) increased by only IPC and TPPC (Figure
5). IPC- and TPPC-induced activation of PKC- in the
particulate fraction was abrogated by pretreatment with
5-HD or a PKC inhibitor chelerythrine. PKC- activity in
the cytosol fraction was not affected by IPC or PPC with
any combinations, but was significantly decreased from the
baseline level by treatment with chelerythrine alone (P 
.01) or in combination with IPC or TPPC (P  .05).
Pretreatment with 5-HD or chelerythrine had no signif-
icant (P .1) effect on baseline hemodynamic variables nor
did it affect IPC-induced and TPPC-induced changes in
LVDP, heart rate, and coronary flow (not shown). Pretreat-
ment with 5-HD or chelerythrine had also no effect on
IPC-induced and TPPC-induced acceleration of ischemic
contracture (Figure 6). However, pretreatment with 5-HD or
chelerythrine inhibited improvement of functional recovery
(Figure 6) and reduction of CK release (Figure 7) induced
by IPC and TPPC, although 5-HD or chelerythrine by itself
had no significant effect (P .2) on functional recovery and
CK release during reperfusion compared to control.
Discussion
We have examined a cardioprotective effect of adenosine, a
mitoKATP channel opener diazoxide, and an NO donor,
SNAP, and compared their efficacy with that conferred by
IPC. We have employed these drugs with a preconditioning
rather than a pretreatment modality because the former
modality provides better therapeutic potential than the lat-
ter. Preconditioning is known to carry a memory of cardio-
protection that lasts 1 to 2 hours after discontinuation of the
preconditioning stimulus and is restored 12 to 24 hours later
and lasts 3 to 4 days. Using the experimental model, which
fulfills the criterion of early preconditioning, we were able
to show that TPPC with adenosine, diazoxide, and SNAP
conferred powerful myocardial protection that was compa-
rable or even superior to IPC, although each drug alone or
in combination with two of them exerted no significant
cardioprotection.
Acute cardioprotective efficacy of single PPC with aden-
osine, diazoxide, or NO donors remains a controversial
issue. There are a number of studies demonstrating that PPC
with each drug alone confers significant myocardial protec-
tion,7,12,13 but at the same time a considerable number of
studies have failed to substantiate cardioprotective effects of
Figure 3. Creatine kinase release during reperfusion. Coronary effluent was collected during 30 minutes of
reperfusion and measured for creatine kinase release. Ischemic preconditioning (IPC) and pharmacological
preconditioning with adenosine (Ad), diazoxide (Dz), and S-nitroso-N-acetyl-penicillamine (SNAP), alone or in
combination with two of them or all of them, were performed according to the protocol as shown in Figure 1. Each
bar graph represents mean  SEM of 6 or 7 experiments. *P < .01 vs control.
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Figure 4. Flavoprotein oxidation during ischemic preconditioning and pharmacological preconditioning. Flavopro-
tein fluorescence was measured as described in Materials and Methods. The upper panel shows representative
traces of flavoprotein fluorescence during ischemic preconditioning (IPC) or pharmacological preconditioning with
diazoxide (Dz) alone or in combination with adenosine (Ad) and S-nitroso-N-acetyl-penicillamine (SNAP) in the
presence or absence of 5-hydroxydecanoate (HD). Flavoprotein oxidation was expressed as a percentage of the
dinitrophenol (DNP)-induced fluorescence. Filled boxes represent ischemia and a scale bar indicates 5 minutes.
The lower panel shows quantitative analysis of maximum flavoprotein oxidation. Each bar graph represents mean
 SEM of 6 experiments. **P < .01 vs IPC, ††P < .01 vs Dz, and #P < .01 vs Ad  Dz  SNAP.
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a single drug treatment.14-16 To the best of our knowledge,
no studies using a single PPC strategy have reported such a
powerful cardioprotection as documented in our study em-
ploying TPPC. It is not surprising to find that only TPPC
mimics IPC, because IPC is mediated by complex signaling
cascades arising from orchestration of multiple triggers. It is
possible that in certain experimental models single PPC can
exert some cardioprotection when other essential co-triggers
are already activated. In support of this notion is the fact that
in a sheep model of regional ischemia and reperfusion a
bolus injection of adenosine before ischemia provided only
marginal protection against stunning and infarction, while
IPC supplemented with adenosine markedly increased car-
dioprotection.17 Our recent study18 has also demonstrated
that adenosine preconditioning had no early benefit in func-
tional protection after global ischemia, although adminis-
tration of adenosine during IPC was capable of significantly
enhancing IPC-induced protection. These observations sug-
gest that adenosine enhancement of IPC-induced cardiopro-
tection is elicited by robust activation of G protein–coupled
adenosine receptors in concert with other yet unidentified
triggers produced by preconditioning ischemia and reperfu-
sion. In this context, it is speculated that mitoKATP channel
activation and NO are the likely co-triggers of successful
Figure 5. Protein kinase C (PKC)--selective phosphorylation activity assay. PKC--selective phosphorylation
activity after ischemic preconditioning (IPC) or pharmacological preconditioning with adenosine (Ad), diazoxide
(Dz), and S-nitroso-N-acetyl-penicillamine (SNAP), in the presence or absence of 5-hydroxydecanoate (HD) or
chelerythrine (Che), was measured in the particulate and the cytosol fractions as described in Materials and
Methods. Each bar graph represents mean  SEM of 6 experiments. *P < .05, **P < .01 vs control, †P < .05, ††P
< .01 vs IPC, and #P < .05 vs Ad  Dz  SNAP.
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Figure 6. Effect of 5-hydroxydecanoate and chelerythrine on ischemic contracture and the recovery of LV function
during reperfusion. TTC indicates time to the onset of ischemic contracture. LVDP R30, HR R30, CF R30, and LVEDP
R30 indicate LV-developed pressure, heart rate, coronary flow, and LV end-diastolic pressure measured at 30
minutes after reperfusion, respectively. Ischemic preconditioning (IPC) or pharmacological preconditioning with
adenosine (Ad), diazoxide (Dz), and S-nitroso-N-acetyl-penicillamine (SNAP), in the presence or absence of
5-hydroxydecanoate (HD) or chelerythrine (Che), was performed according to the protocol as shown in Figure 1.
Each bar graph represents mean  SEM of 6 or 7 experiments. *P < .05, **P < .01 vs control, †P < .05, ††P <
.01 vs IPC, and #P < .05, ##P < .01 vs Ad  Dz  SNAP.
Cardiopulmonary Support and Physiology Uchiyama et al
156 The Journal of Thoracic and Cardiovascular Surgery ● July 2003
CSP
preconditioning with adenosine. Diazoxide was shown to
generate reactive oxygen species,6,7 which have been im-
plicated in the trigger of IPC.19 NO has also been implicated
in the trigger of IPC.9 A recent study20 has shown that
stimulation of G protein–coupled receptors requires con-
comitant presence of reactive oxygen species and NO to
form a signaling complex, which is potentially involved in
enhanced PKC- activity by IPC.11,21 Although it has been
shown that NO alone induces activation of PKC-,22 our
study demonstrating significant activation of PKC- by only
TPPC suggests that this treatment modality is necessary to
promote robust cardioprotective signaling.
Although mitoKATP channel activation appears to be an
essential trigger in both IPC and TPPC because inhibition of
mitoKATP channels with 5-HD abolished cardioprotection
conferred by IPC and TPPC, IPC- and TPPC-induced car-
dioprotection was not associated with enhanced mitoKATP
channel activity over diazoxide alone. Thus, synergistic
cardioprotection induced by TPPC is thought to require
signaling events not only mediated by mitoKATP channel
activation but also those generated by adenosine and an NO
donor. Furthermore, 5-HD or chelerythrine abrogated IPC-
induced and TPPC-induced activation of PKC- and cardio-
protection. Therefore, it is hypothesized that integrated PPC
is achieved by coordinated interaction of three distinct sig-
naling events mediated by adenosine, mitoKATP channel
activation, and NO, which amplifies PKC signaling respon-
sible for cardioprotection.
The role of mitoKATP channels in acquisition of toler-
ance to ischemia afforded by preconditioning is a consid-
erable matter of debate. The notion that mitoKATP channels
act as a trigger of preconditioning comes from a study
demonstrating that diazoxide confers myocardial protection
and simultaneous treatment with 5-HD abolishes protection,
while treatment with 5-HD after diazoxide treatment can not
block protection.6 In contrast, the argument for the distal
effector role of mitoKATP channels in preconditioning is
based on the fact that 5-HD blocked cardioprotection when
administered during ischemia and even reperfusion.23 Puta-
tive actions of mitoKATP channel activation on energy con-
servation and protection against mitochondrial Ca2 over-
load24,25 are consistent with an effector role of mitoKATP
channels in preconditioning. Because the present study con-
firms only the former hypothesis that mitoKATP channel
activation acts as a trigger of cardioprotection conferred by
TPPC, an effector role of mitoKATP channels remains to be
investigated.
MitoKATP channel activity during IPC and TPPC was
evaluated by measuring the native autofluorescence of mi-
tochondrial flavoproteins to monitor the redox state of the
mitochondria.10 The rationale of measuring flavoprotein
fluorescence is based on the hypothesis that opening of any
Figure 7. Effect of 5-hydroxydecanoate and chelerythrine on creatine kinase release during reperfusion. Ischemic
preconditioning (IPC) or pharmacological preconditioning with adenosine (Ad), diazoxide (Dz), and S-nitroso-N-
acetyl-penicillamine (SNAP), in the presence or absence of 5-hydroxydecanoate (HD) or chelerythrine (Che), was
performed according to the protocol as shown in Figure 1. Each bar graph represents mean  SEM of 6 or 7
experiments. *P < .01 vs control, †P < .05 vs IPC, and #P < .05, ##P < .01 vs Ad  Dz  SNAP.
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potassium-selective ion channels in the inner mitochondrial
membrane would tend to dissipate the membrane potential
established by the proton pump. Such dissipation acceler-
ates electron transfer by the respiratory chain and leads to
net oxidation of the mitochondrial matrix. However, there is
an argument against the occurrence of significant uncou-
pling of mitochondrial electron transport by activation of
mitoKATP channels.24 We have observed nearly 50% in-
crease in flavoprotein oxidation during IPC and TPPC.
Increased flavoprotein oxidation during these treatments
may not be attributed solely to uncoupling, because addition
of the mitochondrial uncoupler DNP abolished contraction
and provoked contracture within a few minutes, associated
with a comparable increase in flavoprotein oxidation to that
observed with IPC, diazoxide, and TPPC. In addition, the
increase in flavoprotein oxidation induced by IPC, diazox-
ide, and TPPC but not DNP was inhibited by 5-HD. These
findings suggest that mitoKATP channel activation may also
affect flavoprotein oxidation in a manner distinct from un-
coupling of mitochondrial respiration.
A limitation of our study is that flavoprotein fluorescence
changes are representative of a restricted region of the left
ventricle. The excitation light hits the circular region of
inferoposterior LV wall 1 cm in diameter and penetrates
through the epicardium less than 0.1 mm deep into the
myocardium. The fluorescence change in the middle myo-
cardium and the subendocardium may be different from that
in the subepicardium. It should also be considered that the
fluorescence signal is originated from both cardiomyocytes
and nonmyocytes, although we are interested mainly in
mitoKATP channel activity in cardiomyocytes. Because of
such a potential limitation in evaluating mitoKATP channel
activity in the intact heart, caution must be exerted to
address a complex role of mitoKATP channel activation in
cardioprotection conferred by IPC and TPPC.
Integrated PPC mimics IPC not only with respect to the
efficacy of cardioprotection but also with respect to some
other physiological responses, such as an increase in coro-
nary flow. More interestingly, ischemic contracture was
accelerated by IPC and TPPC. Although accelerated isch-
emic contracture by IPC has also been observed by other
investigators using animal models with global ischemia,26,27
this phenomenon has not been reported in animal models
with regional ischemia. Increased contracture may also oc-
cur in the regionally ischemic myocardium undergoing IPC,
but elevation of LVEDP is probably compensated by en-
hanced relaxation of the nonischemic myocardium. It is
known that ischemic contracture usually occurs as a result
of ATP depletion at the cessation of anaerobic glycolysis.
However, because IPC preserves ATP during index isch-
emia,28 accelerated ischemic contracture may not simply be
explained by cellular ATP depletion. In addition, because
TPPC accelerated ischemic contracture without prior sub-
mission to ischemia, ischemic insult is not an essential
prerequisite for IPC-induced acceleration of ischemic con-
tracture. This observation in turn suggests that common
signaling pathways are involved in enhanced ischemic con-
tracture induced by IPC and TPPC. The fact that the en-
hanced ischemic contracture was not affected by treatment
with 5-HD or chelerythrine, which effectively inhibited
cardioprotection conferred by IPC and TPPC, indicates that
the mechanism of accelerated ischemic contracture is not
mediated by mitoKATP channel or PKC activation.
Doses of pharmacological agents are of prime impor-
tance in determining the efficacy of PPC. We employed
conventional doses of adenosine, diazoxide, and SNAP.
However, adenosine is known to exert cardioprotection via
2 distinct mechanisms. A micromolar order of adenosine
generated during a brief period of ischemia acts as a trigger
of IPC rather than a mediator of cardioprotection, but a
milimolar order of adenosine administered upon ischemia
may be directly cardioprotective via a cardioplegic prop-
erty. Such a high dose of adenosine may not be applicable
in the clinical setting of myocardial protection because of
profound systemic hypotension. The dose of adenosine used
in the present study was 30 mol/L, which has been shown
to increase cardiac interstitial adenosine concentration at
least several times higher than that produced by IPC.29
Equivalent doses of adenosine have been employed in clin-
ical trials of adenosine myocardial protection without a
considerable adverse hemodynamic effect.30 We found that
this dose of adenosine produced acceptable decrease of
heart rate, and combination with diazoxide and SNAP even
mitigated an adenosine-induced negative chronotropic ef-
fect. Duration of preconditioning is also crucial, because
preconditioning stimulus usually imposes stress on the
heart. It has been shown that prolonged treatment with
diazoxide before ischemia discounts the efficacy of precon-
ditioning with diazoxide.31 NO donors also act as a pro-
moter and an inhibitor of cardiomyocyte cell death, depend-
ing on the dose and duration of treatment.32 In the present
study, 25 minutes of PPC was chosen to match the time
frame with the IPC protocol. Our preliminary study dem-
onstrated that 15 minutes of TPPC was long enough to
confer myocardial protection, which was equipotent to the
present PPC protocol, although 5 minutes of TPPC provided
no significant protection (H.O. and colleagues, unpublished
observation).
In conclusion, integrated PPC in combination with aden-
osine, diazoxide, and an NO donor confers synergistic car-
dioprotection that is comparable to that induced by IPC.
This pronounced cardioprotection is not simply mediated by
enhanced mitoKATP channel activation but is presumably
mediated through coordinated interaction of distinct signals
derived from G protein–coupled receptors, mitoKATP chan-
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nels, and NO, which amplifies PKC signaling responsible
for cardioprotection.
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